Clinical Practice Guidelines for Bipolar Disorder
Main Page
Module D
Module E
Module F
Module G
Module H
References
Acknowledgment
Home

 

 

References

Go to Module H.

Go to Main Page.
 

  1. Akiskal HS. Dysthymic and cyclothymic depressions: Therapeutic considerations. J Clin Psychiatry 1994;55(4, suppl):46–52
  2. Alexander RC, Salomon M, Ionescu-Pioggia M, Cole JO. Convulsive therapy in the treatment of mania. Convulsive Ther 1987;3:1–9
  3. Altman E, Hedeker D, Janicak P, Peterson J, Davis J. The clinician-administered rating scale for mania (CARS-M): Development, reliability, and validity. Biol Psychiatry 1994;36:124–134
  4. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am J Psychiatry 1995;152:1130–1138
  5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994
  6. American Psychiatric Association. Tardive dyskinesia: A task force of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1991
  7. Baldessarini R, Suppes T, Tondo L. Lithium withdrawal in bipolar disorder: Implications for clinical practice and experimental therapeutics research. Am J Ther 1996;3:392–396
  8. Baldessarini R, Tondo L, Suppes T, Faedda G, Tohen M. Pharmacologic treatment of bipolar disorder throughout the life cycle. In: Mood Disorders Across the Life Span. Shulman K, Tohen M, Kutcher S (Eds). New York, NY: Wiley Press; 1996:299–336
  9. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: A new treatment. Am J Psychiatry 1980;137:782–790
  10. Baron M, Gershon ES, Rudy V, Jonas WZ, Bushsbaum M. Lithium carbonate response in depression. Prediction by unipolar/bipolar illness, average-evoked response, catechol-o-methyl transferase, and family history. Arch Gen Psychiatry 1975;23:1107–1111
  11. Basco M, Rush AJ. Cognitive-Behavioral Therapy for Bipolar Disorder. New York, NY: Guilford Press; 1996
  12. Bauer M, Calabrese J, Dunner D, Post R, Whybrow P, Gyulai L, Tay L, Younkin S, Bynum D, Lavori P, Price RA. Multi-site data reanalysis: Rapid cycling as a modifier for bipolar disorder in DSM-IV. Am J Psychiatry 1994;151:506–515
  13. Bauer M, Crits-Christoph P, Ball W, Dewees E, McAllister T, Alahi P, Cacciola J, Whybrow P. Independent assessment of manic and depressive symptoms by self-rating. Arch Gen Psychiatry 1991;48:807–812
  14. Bauer M, McBride L. Psychoeducation: Conceptual framework and practical considerations. J Practical Psychiatry Behav Health (In press)
  15. Bauer M, McBride L. The Life Goals Program: Structured Group Psychotherapy for Bipolar Disorder. New York, NY: Springer Publishing; 1996
  16. Bauer M, Shea N, McBride L, Gavin C. Predictors of service utilization in veterans with bipolar disorder: A prospective study. J Affect Disord (In press)
  17. Bauer M, Whybrow P. Rapid cycling bipolar affective disorder, II: Adjuvant treatment of refractory rapid cycling with high dose thyroxine. Arch Gen Psychiatry 1990;47:435–440
  18. Bauer M, Whybrow P. Rapid cycling bipolar disorder: Clinical features, treatment, and etiology. Adv Neuropsychiatry Psychopharmacol 1991;2:191
  19. Bauer M, Whybrow P. Validity of rapid cycling as a modifier for bipolar disorder in DSM-IV. Depression 1993;1:11–19
  20. Bauer M. Rapid cycling: Current issues and treatment strategies. In: Anticonvulsants in Psychiatry. Calabrese J, Joffe R (Eds). New York, NY: Marcel Dekker; 1994:1–25
  21. Bauer M. Summertime bright light treatment of nonseasonal major depressive episodes in bipolar disorder. Biol Psychiatry 1993;33:563–565
  22. Beasley JC, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Presented at the 150th Annual Meeting of the American Psychiatric Association; May 17–22, 1997; San Diego, Calif
  23. Beck AT, Ward C, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571
  24. Black DW, Winokur G, Nasrallah A. Treatment of mania: A naturalistic study of electroconvulsive therapy versus lithium in 438 patients. J Clin Psychiatry 1987;48:132–139
  25. Bland R, Orn H. Course and outcome in affective disorders. Can J Psychiatry 1982;27:573
  26. Bouman T, Niemanstverdriet van Kampen J, Ormel J, Sloof C. The effectiveness of lithium prophylaxis in bipolar and unipolar depressions and schizoaffective disorders. J Affect Disord 1986;11:275–280
  27. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SD, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD. Efficacy of divalproex versus lithium versus placebo in the treatment of mania. JAMA 1994;271:918–924
  28. Bowden CL, Janicak PG, Orsulak P, Swann AC, Davis JM, Calabrese JR, Goodnick P, Small JG, Rush JA, Kimmel SE, Risch SC, Morris DD. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996;153:765–770
  29. Bowden CL. Dosing strategies and time course of response to antimanic drugs. J Clin Psychiatry 1996;57(suppl 13):4–9
  30. Bowden CL. Role of newer medications for bipolar disorder. J Clin Psychopharmacol 1996;16(suppl 1):48S–55S
  31. Bradwejn J, Shiriqui C, Koszycki D, Meterissian G. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990;10:403–408
  32. Bunney WE Jr, Goodwin FK, Murphy DL, House KM, Gordon EK. The "switch process" in manic-depressive illness. II. Relationship to catecholamines, REM sleep, and drugs. Arch Gen Psychiatry 1972;27:304–309
  33. Bunney WE Jr, Goodwin FK, Murphy DL. The "switch process" in manic-depressive illness. III. Theoretical implications. Arch Gen Psychiatry 1972;27:312–317
  34. Bunney WE Jr, Murphy DL, Goodwin FK, Borge GF. The "switch process" in manic-depressive illness. I. A systematic study of sequential behavioral changes. Arch Gen Psychiatry 1972;27:295–302
  35. Calabrese J, Faterni SH, Woyshville M. Antidepressant effects of lamotrigene in rapid cycling bipolar disorder [letter]. Am J Psychiatry 1996;153:1236
  36. Calabrese J, Meltzer H, Markovitz P. Clozapine prophylaxis in rapid cycling bipolar disorder. J Clin Psychopharmacol 1991;11:396–397
  37. Calabrese JR, Bowden CL, McElroy S, Cookson J, Anderson J, Rhodes L, Woyshville M, Keck P, Kundu S, Paterson G, Ascher J, Bolden-Watson C. Efficacy of lamotrigine in bipolar disorder: Premininary data. In: Mechanism of Antibipolar Treatments: Focus on Lithium, Valproate, and Carbamazepine. Manjhi HK, Bowden C, Belmaker R (Eds). Washington, DC: American Psychiatric Association; 1997
  38. Calabrese JR, Bowden CL, Rhodes LJ, et al. Lamotrigine in treatment refractory bipolar disorder. Presented at the 149th Annual Meeting of the American Psychiatric Association; May 4–9, 1996; New York, NY
  39. Calabrese JR, et al. Mixed states and bipolar rapid cycling and their treatment with valproate. Psychiatr Ann 1993;23:70–78
  40. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759–764
  41. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid cycling bipolar patients. J Clin Psychopharmacol 1992;12:53S–56S
  42. Chouinard G. Clonazepam in acute and maintenance treatment of bipolar affective disorder. J Clin Psychiatry 1987;48(10, suppl):29–37
  43. Cohen LS, Sichel OA, Robertson LM, Heckscher E, Rosenbaum JF. Postpartum prophylaxis for women with bipolar disorder. Am J Psychiatry 1995;152:1841–1845
  44. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine, imipramine and placebo in patients with bipolar affective disorder. Int J Clin Psychopharmacol 1989;4:313–332
  45. Cooper TB, Bergner PE, Simpson GM. The 24-hour serum lithium level as a prognosticator of dosage requirements. Am J Psychiatry 1973;130:601–603
  46. Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder: Demographics, diagnosis, family history, and course. Arch Gen Psychiatry 1991;49:126–131
  47. Deltito JS, Moline M, Pollak C, Martin LY, Maremmani I. Effect of phototherapy on nonseasonal unipolar and bipolar depressive spectrum disorders. J Affect Disord 1991;23:231–237
  48. Delucchi GA, Calabrese JR. Anticonvulsants for treatment of manic depression. Cleve Clin J Med 1989;56:756–761
  49. Dilsaver SC, Swann AC, Chen Y, Shoaib A, Joe B, Krajewski KJ, Gruber N, Tsai Y. Treatment of bipolar depression with carbamazepine: Results of an open study. Biol Psychiatry 1996;40:935–937
  50. Donnelly EF, Goodwin FK, Waldman IN, Murphy DL. Prediction of antidepressant response to lithium. Am J Psychiatry 1978;135:552–556
  51. Dubovsky SL, Franks RD, Allen S, Murphy J. Calcium-channel antagonists in mania: A double-blind study of verapramil. Psychiatry Res 1986;18:309–320
  52. Dunner D, Tay L. Diagnostic reliability of the history of hypomania in bipolar II patients and patients with major depression. Compr Psychiatry 1993;34:303–307
  53. Dunner DL, Fieven RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974;30:229–233
  54. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985;8:243–250
  55. Faedda G, Tondo L, Baldessarini R, Suppes T, Tohen M. Outcome after rapid versus gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993;50:448–455
  56. Fieve RR, Platman SR, Plutchik RR. The use of lithium in affective disorders I: Acute endogenous depression. Am J Psychiatry 1968;125:487–491
  57. First MB, Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-IV. New York, NY: Biometric Research, New York State Psychiatric Institute and Columbia University; 1996
  58. Frances A, Docherty J, Kahn D. The Expert Consensus Guideline Series: Treatment of Bipolar Disorder. J Clin Psychiatry 1996;57(suppl 12A):1–80
  59. Frank E, Kupfer D, Ehlers C, Monk T, Cornes C, Carter S, Frankel D. Interpersonal and social rhythm therapy for bipolar disorder: Integrating interpersonal and behavioral approaches. Behav Ther 1994;17:143–149
  60. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992;149:108–111
  61. Gelenberg A, Kane J, Keller M, Lavori P, Rosenbaum J, Cole K, Lavelle J. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321:1489–1493
  62. Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. J Clin Psychiatry 1996;57(suppl 9):49–56
  63. Gelenberg AJ. Catatonic syndrome. Lancet 1976;1:1339–1341
  64. Ghadirian AM, Annable L, Belanger MC. Lithium, benzodiazepines, and sexual function in bipolar patients. Am J Psychiatry 1992;149:801–805
  65. Goldstein M, Miklowitz D. Family intervention for persons with bipolar disorder. In: Family Interventions in Mental Illness. Hatfield A (Ed). San Francisco, Calif: Jossey-Bass; 1994:23–35
  66. Goodwin FK, Jamison KR. Manic Depressive Illness. New York, NY: Oxford University Press; 1990
  67. Goodwin FK, Murphy DL, Bunney WE Jr. Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study. Arch Gen Psychiatry 1969;21:486–496
  68. Goodwin FK, Murphy DL, Dunner DL, Bunney WE Jr. Lithium response in unipolar versus bipolar depression. Am J Psychiatry 1972;129:44–47
  69. Gottschalk A, Bauer M, Whybrow P. Evidence for chaotic mood variation in bipolar disorder. Arch Gen Psychiatry 1995;53:947–959
  70. Grossi E, Sacchetti E, Vita A, Conte G, Faravelli C, Hautman G, Zerbi D, Mesina AM, Drago F, Motta A. Carbamazepine versus chlorpromazine in mania: A double-blind trial. In: Anticonvulsants in Affective Disorders. HM Emrich, T Okuma, AA Muller (Eds). Amsterdam, the Netherlands: Excerpta Medica; 1984:177–187
  71. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62
  72. Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar II patients. J Clin Psychiatry 1990;51:450–455
  73. Himmelhoch JM, Fuchs CZ, Symons BJ. A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 1982;170:628–634
  74. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148:910–916
  75. Hirschfeld RMA (Chairman). Workgroup on bipolar disorder. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 1996;151:12(suppl):1–36
  76. Howland RH. Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 1996;16:425–427
  77. Hurowitz GI, Liebowitz MR. Antidepressant-induced rapid cycling: Six case reports. J Clin Psychopharmacol 1993;13:52–56
  78. Jacobson FM. Low-dose valproate: A new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J Clin Psychiatry 1993;54:229–234
  79. Janicak PG, Davis JM, Preskorn SH, Ayd FJ. Principles and Practice of Psychopharmacotherapy. Baltimore, Md: Williams & Wilkins; 1993
  80. Joffe RT, Levitt AJ, Sokolov STH. Augmentation strategies: Focus on anxiolytics. J Clin Psychiatry 1996;57(suppl 7):25–31
  81. Johnson G, Gershon S, Burdock EI, Floyd A, Hekimian L. Comparative effects of lithium and chlorpromazine in the treatment of acute manic sates. Br J Psychiatry 1971;119:267–276
  82. Johnson G, Gershon S, Hekimian LJ. Controlled evaluation of lithium and chlorpromazine in the treatment of acute manic states: An interim report. Compr Psychiatry 1968;9:563–573
  83. Kahn D, Ross R, Rush AJ, Panico S. The Expert Consensus Treatment Guidelines for Bipolar Disorder: A guide for patients and families. J Clin Psychiatry 1996;57(suppl 12A):81–88
  84. Kahn DA, Carpenter D, Docherty JF, Frances A. The expert consensus guideline series: Treatment of bipolar disorder. Expert Knowledge Systems LLC; 1996
  85. Kanas N. Group psychotherapy with bipolar patients: A review and synthesis. Int J Group Psychother 1993;43:321–333
  86. Kanas N. Group psychotherapy with schizophrenia. In: Comprehensive Group Psychotherapy. Kaplan H, Sadock B (Eds). Baltimore, Md: Williams & Wilkins; 1993:407–417
  87. Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiatry 1988;45:789–796
  88. Kane JM. The role of neuroleptics in manic-depressive illness. J Clin Psychiatry 1988;49(suppl 11):12–13
  89. Keck PE Jr, McElroy SL, Strakowski SM. New developments in the pharmacologic treatment of schizoaffective disorder. J Clin Psychiatry 1996;57(suppl 9):41–48
  90. Keck PE Jr, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM, Holtman HM, DePriest M. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995;56:466–470
  91. Keitner G, Miller I, Ryan C. Adjunctive family treatment of bipolar disorder. Presented at the 10th World Congress of Psychiatry; August 24, 1996; Madrid, Spain
  92. Kessel A, Holt F. A controlled study of a tetracyclic antidepressant-maproptiline (ludiomil). Med J Aust 1975;1:773–336
  93. Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell T, Post RM. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol (In press)
  94. Ketter TA, Pazzaglia PJ, Post RM. Synergy of carbamazepine and valproic acid in affective illness: Case report and review of the literature. J Clin Psychopharmacol 1992;12:276–281
  95. Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine. Part I. J Clin Psychopharmacol 1991;11:198–203
  96. Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine. Part II. J Clin Psychopharmacol 1991;11:306–313
  97. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol versus placebo and haloperidol in excited psychosis: A controlled study. Arch Gen Psychiatry 1984;41:165–170
  98. Kramlinger KG, Post RM. The addition of lithium to carbamazepine: Antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry 1989;46:794–800
  99. Kufferle B. Group dynamics as emotional turmoil precipitating psychotic manifestations. Psychopathology 1988;21:111–115
  100. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmacopsychiatric-Neuropsychopharmacol 1980;13:156–167
  101. Lambert M, Petty F. The Teaching Interview for Psychiatric Students, TIPS. 1996. Available from the authors at: Dallas VAMC– 116A, 4500 South Lancaster Rd., Dallas TX 75216
  102. Lambert PA, Venaud G. The use of valpromide in psychiatry. Encephale 1987;13:367–373
  103. Lambert PA. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Anticonvulsants in Affective Disorders. Emrich HM, Okuma T, Muller AA (Eds). Amsterdam, the Netherlands: Excerpta Medica; 1984:33–44
  104. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: A double-blind study. J Clin Psychiatry 1992;53:47–52
  105. Lenzi A, Lazzerini F, Placidi GF, Cassano, Akiskal HS. Predictors of compliance with lithium and carbamazepine in the long-term treatment of recurrent mood and related psychotic disorders. Pharmacopsychiatry 1989;22:34–37
  106. Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S. Carbamazepine versus lithium in mania: A double-blind study. J Clin Psychiatry 1987;48:89–93
  107. Lerner Y, Lwow E, Levitin A, Belmaker RH. Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatry 1979;136:1061–1064
  108. Lowe M, Batchelor D. Depot neuroleptics and manic-depressive psychosis. Int J Clin Psychopharmacol 1986;1:53–62
  109. Lundqvist G. Prognosis and course in manic-depressive psychosis. Acta Psychiatr Neurol Scand 1945;35:1
  110. Maggs R. Treatment of manic illness with lithium carbonate. Br J Psychiatry 1987;150:863–864
  111. Maj M, Pirozzi R, Magliano L. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: Prevalence and predictors. Am J Psychiatry 1995;152:1810–1811
  112. Mann SC, Caroff SN, Bleier HR, Anttelo RE, Un H. Electroconvulsive therapy of the lethal catatonia syndrome. Convulsive Ther 1990;6:239–247
  113. Marder S, Meibach R. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825–835
  114. McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, Aizley HG, OÌBrien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:4411–4414
  115. McElroy SL, Keck PE Jr, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57:142–146
  116. McElroy SL, Soutullo CA, Keck PE Jr, Kmetz GF. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin Psychiatry 1997;9:99–103
  117. Mendels J. Lithium in the treatment of depression. Am J Psychiatry 1976;133:373–378
  118. Miklowitz D, Goldstein M. Behavioral family treatment for patients with bipolar affective disorder. Behav Modif 1990;14:457–489
  119. Miklowitz D. Psychotherapy in combination with drug treatment for bipolar disorder. J Clin Psychopharmacol 1996;16(suppl 1):56S–66S
  120. Moller HJ, Kissling W, Riehl T, Bauml J, Binz U, Wendt G. Double-blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Prog Neuropsychopharmocol Biol Psychiatry 1989;13:127–136
  121. Mukherjee S, Rosen AM, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986;43:342–346
  122. Mukherjee S, Sackeim HA, Lee C. Unilateral ECT in the treatment of manic episodes. Convulsive Ther 1988;4:74–80
  123. Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: A review. Am J Psychiatry 1994;151:169–176
  124. Muller AA, Stoll KD. Carbamazepine and oxcarbamazepine in the treatment of manic syndromes: Studies in Germany. In: Anticonvulsants in Affective Disorders. Emrich HM, Okuma T, Muller AA (Eds). Amsterdam, the Netherlands: Excerpta Medica; 1984:139–147
  125. Muller-Oerlinghausen B, Muser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992;25:261–270
  126. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995;52:1500–1503
  127. Nilsson A. Mortality in recurrent mood disorders during periods on and off lithium: A complete population study in 362 patients. Pharmacopsychiatry 1995;28:8–13
  128. Noyes R, Dempsey GM, Blum A, Cavanaugh GL. Lithium treatment of depression. Compr Psychiatry 1974;15:187–193
  129. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe M. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study. Psychopharmacology (Berl) 1979;66:211–217
  130. Okuma T, Kishimoto A, Inoue K. Antimanic and prophylactic effects of carbamazepine (Tegretol) on manic-depressive psychosis. Seishin Igaku 1975;17:617–630
  131. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;1:799–812
  132. Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164:549–550
  133. Platman SR. A comparison of lithium carbonate and chlorpromazine in mania. Am J Psychiatry 1970;127:351–353
  134. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania: A placebo-controlled study. Arch Gen Psychiatry 1991;48:62–68
  135. Post R, Roy-Byrne P, Uhde T. Graphic representation of the life course of illness in patients with affective disorders. Am J Psychiatry 1988;145:844–848
  136. Post RM, Leverich GS, Rosoff AS, Altshuler LL. Carbamazepine prophylaxis in refractory affective disorders: A focus on long-term follow-up. J Clin Psychpharmacol 1990;10:318–327
  137. Post RM, Uhde TW, Ballenger JC, Chatterji DC, Greene RF, Bunney WE, Jr. Carbamazepine and its –10, 11-epoxide metabolite in plasma and CSF: Relationship to antidepressant response. Arch Gen Psychiatry 1983;40:673–676
  138. Post RM, Uhde TW, Ballenger JC, Squillace KM. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 1983;140:1602–1604
  139. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 1986;143:29–34
  140. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Correlates of antimanic responses to carbamazepine. Psychiatry Res 1987;21:71–83
  141. Prien RF, Caffey EM, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health collaborate study group. Arch Gen Psychiatry 1972;26:146–153
  142. Prien RF, Gelenberg AJ. Alternatives to lithium for preventive treatment of bipolar disorder. Am J Psychiatry 1989;146:840–848
  143. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res 1990;31:287–296
  144. Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391–393
  145. Sachs GS, Weilburg JB, Rosenbaum JF. Clonazepam versus neuroleptics as adjuncts to lithium maintenance. Psychopharmacol Bull 1990;26:137–143
  146. Sachs GS. Bipolar mood disorder: Practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 1996;16:32S–47S
  147. Schooler NR. Maintenance medication for schizophrenia: Strategies for dose reduction [review]. Schizophr Bull 1991;17:311–324
  148. Schou M, Juel-Nielson N, Stomgren E, Voldby H. The treatment of manic psychosis by administration of lithium salts. J Neurol Neurosurg Psychiatry 1954;17:250–260
  149. Sernyak MJ, Woods SW. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull 1993;29:375–381
  150. Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 1975;32:34–42
  151. Small JG, Klapper MH, Kellams JJ, Miller MJ, Milstein V, Sharpley PH, Small IF. Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry 1988;45:727–732
  152. Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, Small IF. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991;48:915–921
  153. Solomon P, Meyerson A. Social stabilization: Achieving satisfactory community adaptation for the disabled mentally ill. In: (*) Tasman A, Kay J, Lieberman J (Eds). Philadelphia, Pa: Saunders; 1997:1727–1750
  154. Spring G, Schweid D, Gray C, Steinberg J, Horwitz M. A double-blind comparison of lithium and chlorpromazine in the treatment of manic states. Am J Psychiatry 1970;126:1306–1310
  155. Srisurapanont M, Yatham L, Zis A. Treatment of acute bipolar depression: A review of the literature. Can J Psychiatry 1995;40:533–543
  156. Stancer HC, Persad E. Treatment of intractable rapid-cycling manicdepressive disorder with levothyroxine: Clinical observatians. Arch Gen Psychiatry 1982;39:311–312
  157. Stein D, Avni J. Thyroid hormone in the treatment of affective disorders. Acta Psychiatr Scand 1988;77:623–636
  158. Stokes PE, Koesis JH, Arcuni OJ. Relationship of lithium chloride dose to treatment response in acute mania. Arch Gen Psychiatry 1976;33:1080–1084
  159. Stokes PE, Shamoian CA, Stoll PM, Patton MJ. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971;1:1319–1325
  160. Stoll AL, Mayer PV, Kolbrener M, Goldstein E, Suplit B, Lucier J, Cohen BM, Tohen M. Antidepressant-associated mania: A controlled comparison with spontaneous mania. Am J Psychiatry 1994;151:1642–1645
  161. Stoll AL, Sachs GS, Cohen BM, Lafer B, Christensen JD, Renshaw PF. Choline in the treatment of rapid-cycling bipolar disorder: Clinical and neurochemical findings in lithium-treated patients. Biol Psychiatry 1996;40:382–388
  162. Suppes T, Baldessarini R, Faedda G, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082–1088
  163. Suppes T, Baldessarini R, Faedda G, Tondo L, Tohen M. Discontinuation of maintenance treatment in bipolar disorder: Risks and implications. Harvard Rev Psychiatry 1993;1:131–144
  164. Suppes T, McElroy SL, Gilbert T, Dessain EC, Cole JC. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270–280
  165. Suppes T, Rush AJ, Webb A, Cannody T, Kraemner H. A one-year randomized trial of clozapine vs. usual care in bipolar I patients. Presented at the 51st Annual Meeting of the Society for Biological Psychiatry; May 4, 1996; New York, NY
  166. Swann AC, Bowden CL, Morris D. Calabrese JR, Petty F, Small J, Dilsaver SC, Davis JM. Depression during mania: Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54:37–42
  167. Takahashi R, Sakuma A, Itoh K, Itoh H, Kurihara M. Comparison of efficacy of lithium carbonate and chlorpromazine in mania: Report of collaborative study group on treatment of mania in Japan. Arch Gen Psychiatry 1975;32:1310–1318
  168. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149:195–198
  169. The Expert Consensus Guideline Series: Treatment of Bipolar Disorder. J Clin Psychiatry 1996;57(suppl 12A):2–89
  170. Tohen M, Castillo J, Pope HG Jr, Herbstein J. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994;14:67–70
  171. Tohen M, Waternaux CM, Tsuang MT, Hunt AT. Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord 1990;19:79–86
  172. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990;47:1106–1111
  173. Vesely C, Fischer P, Goessler R, Kasper S. Mania associated with serotonin selective reuptake inhibitors [letter]. J Clin Psychiatry 1997;58:88
  174. Watanabe S, Ishino H, Otsuki S. Double-blind comparison of lithium carbonate and imipramine in treatment of depression. Arch Gen Psychiatry 1975;32:659–668
  175. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987;144:1403–1411
  176. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1997;36:555–559
  177. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. J Clin Psychiatry 1989;50:447–449
  178. Weisler RH, Risner ME, Ascher JA, Houser TL. Use of lamotrigine in the treatment of bipolar disorder. In: New Research Program and Abstracts of the 147th Annual Meeting of the American Psychiatric Association; May 26, 1994; Philadelphia, Pa. Abstract NR611:216
  179. Wright G, Galloway L, Kim J, Dalton M, Miller L, Stern W. Bupropion in the long-term treatment of cyclic mood disorders: Mood stabilizing effects. J Clin Psychiatry 1985;46:22–25
  180. Zarin D, Pass T. Lithium and the single episode: When to begin long-term prophylaxis for bipolar disorder. Med Care 1987;25:876–884
  181. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: New directions for research. J Clin Psychopharmacol 1993;13:397–408

Go to Module H.

Go to Main Page.
Main Page | Module D | Module E | Module F | Module G | Module H | References | Acknowledgment | Home